On Monday, Eli Lilly and Company (NYSE:LLY) agreed to acquire a manufacturing facility from Nexus Pharmaceuticals. The deal terms were not disclosed. The acquisition of this FDA-approved facility in Pleasant Prairie, Wisconsin, will further expand Lilly’s global parenteral (injectable) product manufacturing network and support increased demand for the company’s medicines.  Related: Novo Nordisk/Eli Lilly’s Weight Loss Drugs Does Not Cause Suicidal Behaviors – After FDA, European Medicines Agency Says. Lilly estimates that production at this facility could begin at the end of 2025. The Pleasant Prairie facility does not provide contract manufacturing services, allowing the facility to be solely dedicated to Lilly’s manufacturing. Eli Lilly is grappling with a ...